tradingkey.logo


Jupiter Neurosciences Inc

JUNS
1.100USD
-0.020-1.79%
āļ›āļīāļ” 12/19, 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
37.72MāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM


āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Jupiter Neurosciences Inc āļšāļĢāļīāļĐāļąāļ—

Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.

āļ‚āđ‰āļ­āļĄāļđāļĨ Jupiter Neurosciences Inc


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™JUNS
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Jupiter Neurosciences Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļDec 03, 2024
āļ‹āļĩāļ­āļĩāđ‚āļ­Rosen (Christer)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™4
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Dec 03
āļ—āļĩāđˆāļ­āļĒāļđāđˆ1001 North US HWY 1, Suite 504
āđ€āļĄāļ·āļ­āļ‡PALM BEACH GARDENS
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX - NASDAQ BASIC
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ33477
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ15614066154
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://jupiterneurosciences.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™JUNS
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļDec 03, 2024
āļ‹āļĩāļ­āļĩāđ‚āļ­Rosen (Christer)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Jupiter Neurosciences Inc


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Christer Rosen
Mr. Christer Rosen
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
11.08M
--
Mr. Alexander Gustaf Erik Rosen
Mr. Alexander Gustaf Erik Rosen
Co-Founder, Chief Administrative Officer
Co-Founder, Chief Administrative Officer
452.86K
--
Ms. Alison D Silva
Ms. Alison D Silva
President, Chief Business Officer, Director
President, Chief Business Officer, Director
112.78K
--
Mr. Nicholas H. Hemmerly
Mr. Nicholas H. Hemmerly
Independent Director
Independent Director
95.55K
--
Ms. Allison W. Brady
Ms. Allison W. Brady
Independent Director
Independent Director
21.75K
--
Mr. Holger Weis, CPA
Mr. Holger Weis, CPA
Independent Director
Independent Director
10.78K
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Julie Kampf
Ms. Julie Kampf
Independent Director
Independent Director
--
--
Dr. Marshall A Hayward, Ph.D.
Dr. Marshall A Hayward, Ph.D.
Co-Founder, Chief Scientific Officer, Director
Co-Founder, Chief Scientific Officer, Director
--
--
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Christer Rosen
Mr. Christer Rosen
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
11.08M
--
Mr. Alexander Gustaf Erik Rosen
Mr. Alexander Gustaf Erik Rosen
Co-Founder, Chief Administrative Officer
Co-Founder, Chief Administrative Officer
452.86K
--
Ms. Alison D Silva
Ms. Alison D Silva
President, Chief Business Officer, Director
President, Chief Business Officer, Director
112.78K
--
Mr. Nicholas H. Hemmerly
Mr. Nicholas H. Hemmerly
Independent Director
Independent Director
95.55K
--
Ms. Allison W. Brady
Ms. Allison W. Brady
Independent Director
Independent Director
21.75K
--
Mr. Holger Weis, CPA
Mr. Holger Weis, CPA
Independent Director
Independent Director
10.78K
--

āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰

āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡āļĒāļąāļ‡āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāđ€āļ›āļīāļ”āđ€āļœāļĒāļˆāļēāļāļ—āļēāļ‡āļšāļĢāļīāļĐāļąāļ—
āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡āļĒāļąāļ‡āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāđ€āļ›āļīāļ”āđ€āļœāļĒāļˆāļēāļāļ—āļēāļ‡āļšāļĢāļīāļĐāļąāļ—
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡āļĒāļąāļ‡āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāđ€āļ›āļīāļ”āđ€āļœāļĒāļˆāļēāļāļ—āļēāļ‡āļšāļĢāļīāļĐāļąāļ—

āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™

āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļĻāļļāļāļĢāđŒāļ—āļĩāđˆ 28 āļž.āļĒ.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļĻāļļāļāļĢāđŒāļ—āļĩāđˆ 28 āļž.āļĒ.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Rosen (Christer)
32.18%
Wahlestedt (Claes M.D., Ph.D.)
8.14%
Hayward (Marshall A Ph.D.)
6.91%
Brothers (Shaun P.)
4.94%
Vestor Capital Partners, LLC
2.82%
āļ­āļ·āđˆāļ™ āđ†
45.01%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Rosen (Christer)
32.18%
Wahlestedt (Claes M.D., Ph.D.)
8.14%
Hayward (Marshall A Ph.D.)
6.91%
Brothers (Shaun P.)
4.94%
Vestor Capital Partners, LLC
2.82%
āļ­āļ·āđˆāļ™ āđ†
45.01%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Individual Investor
54.10%
Investment Advisor
3.46%
Investment Advisor/Hedge Fund
0.37%
Research Firm
0.07%
Venture Capital
0.04%
āļ­āļ·āđˆāļ™ āđ†
41.95%

āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 1 āļ•.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 1 āļ•.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q3
9
375.55K
1.09%
-18.85K
2025Q2
18
19.49M
58.89%
+1.54M
2025Q1
16
18.33M
55.39%
+383.02K
2024Q4
9
17.92M
54.13%
+14.81M
2024Q3
6
5.31M
79.52%
--
2024Q2
10
5.31M
79.52%
-11.63K
2024Q1
10
5.31M
79.52%
-11.63K
2023Q4
10
5.31M
79.52%
-11.63K
2023Q3
10
5.31M
79.52%
-11.63K
2023Q2
10
5.31M
79.52%
-11.63K
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™


āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
Rosen (Christer)
11.55M
33.17%
+3.60K
+0.03%
Jul 01, 2025
Wahlestedt (Claes M.D., Ph.D.)
2.80M
8.05%
--
--
Mar 12, 2025
Hayward (Marshall A Ph.D.)
2.38M
6.83%
--
--
Mar 12, 2025
Brothers (Shaun P.)
1.70M
4.88%
--
--
Mar 12, 2025
Rosen (Alexander Gustaf Erik)
452.86K
1.3%
--
--
Mar 12, 2025
Silva (Alison D)
112.78K
0.32%
+750.00
+0.67%
Jul 01, 2025
Geode Capital Management, L.L.C.
15.86K
0.05%
--
--
Aug 31, 2025
Elmasri (Saleem C)
66.29K
0.19%
+66.29K
--
Jun 02, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0%

āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ


āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™


āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļ„āļģāļ–āļēāļĄāļ—āļĩāđˆāļžāļšāļšāđˆāļ­āļĒ

āđƒāļ„āļĢāļ„āļ·āļ­āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Jupiter Neurosciences Inc?


āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Jupiter Neurosciences Inc āđ„āļ”āđ‰āđāļāđˆ:
Rosen (Christer) āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 11.55M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 33.17% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
Wahlestedt (Claes M.D., Ph.D.) āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 2.80M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 8.05% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
Hayward (Marshall A Ph.D.) āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 2.38M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 6.83% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
Brothers (Shaun P.) āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 1.70M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 4.88% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
Rosen (Alexander Gustaf Erik) āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 452.86K āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 1.30% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”

āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŠāļēāļĄāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Jupiter Neurosciences Inc āļ„āļ·āļ­āļ­āļ°āđ„āļĢ?


āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŠāļēāļĄāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Jupiter Neurosciences Inc āđ„āļ”āđ‰āđāļāđˆ
Rosen (Christer)
Wahlestedt (Claes M.D., Ph.D.)
Hayward (Marshall A Ph.D.)

āļĄāļĩāļāļĩāđˆāļŠāļ–āļēāļšāļąāļ™āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Jupiter Neurosciences Inc (JUNS)?


āļ“ āļ§āļąāļ™āļ—āļĩāđˆ 2025Q3 āļĄāļĩāļŠāļ–āļēāļšāļąāļ™āļˆāļģāļ™āļ§āļ™ 9 āđāļŦāđˆāļ‡āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Jupiter Neurosciences Inc āđ‚āļ”āļĒāļĄāļĩāļĄāļđāļĨāļ„āđˆāļēāļĢāļ§āļĄāļ›āļĢāļ°āļĄāļēāļ“ 375.55K āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 1.09% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ” āđ€āļĄāļ·āđˆāļ­āđ€āļ—āļĩāļĒāļšāļāļąāļšāļ§āļąāļ™āļ—āļĩāđˆ 2025Q2 āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™āđ„āļ”āđ‰āđ€āļžāļīāđˆāļĄāļ‚āļķāđ‰āļ™ -57.80%

āđāļŦāļĨāđˆāļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļŦāļĨāļąāļāļ‚āļ­āļ‡ Jupiter Neurosciences Inc āļ„āļ·āļ­āļ­āļ°āđ„āļĢ?


āđ€āļĄāļ·āđˆāļ­āļ§āļąāļ™āļ—āļĩāđˆ -- āļ˜āļļāļĢāļāļīāļˆāļ”āđ‰āļēāļ™ -- āļŠāļĢāđ‰āļēāļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļŠāļđāļ‡āļŠāļļāļ”āđƒāļŦāđ‰āļāļąāļš Jupiter Neurosciences Inc āļ„āļīāļ”āđ€āļ›āđ‡āļ™āļĄāļđāļĨāļ„āđˆāļē -- āđāļĨāļ°āļ„āļīāļ”āđ€āļ›āđ‡āļ™ --% āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļĢāļ§āļĄ
KeyAI
î™